From a financial standpoint, 2016 was terrific for Bristol-Myers Squibb. Revenue jumped more than 25% year over year in the first three quarters. Earnings more than doubled. Can the big drugmaker perform as well in 2017? Here are three of the biggest risks that Bristol-Myers Squibb faces in the new year.
